Quadrant Capital Group LLC Intellia Therapeutics, Inc. Transaction History
Quadrant Capital Group LLC
- $1.42 Billion
- Q3 2024
A detailed history of Quadrant Capital Group LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 43 shares of NTLA stock, worth $650. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43
Previous 613
92.99%
Holding current value
$650
Previous $13,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding NTLA
# of Institutions
312Shares Held
91.4MCall Options Held
417KPut Options Held
824K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.3MShares$185 Million2.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.63MShares$146 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$145 Million0.0% of portfolio
-
State Street Corp Boston, MA5.14MShares$77.8 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.95MShares$74.8 Million3.75% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.15B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...